佰仁医疗(688198)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

688198 佰仁医疗

已收盘 03-23 15:00:01

{"stockData":{"symbol":"688198","market":"SH","secType":"STK","nameCN":"佰仁医疗","latestPrice":93.4,"timestamp":1774249201000,"preClose":97.51,"halted":0,"volume":370467,"delay":0,"changeRate":-0.0421,"floatShares":138000000,"shares":138000000,"eps":1.3092,"marketStatus":"已收盘","change":-4.11,"latestTime":"03-23 15:00:01","open":97.6,"high":97.6,"low":93.4,"amount":35112800,"amplitude":0.0431,"askPrice":93.46,"askSize":25,"bidPrice":93.4,"bidSize":8,"shortable":0,"etf":0,"ttmEps":1.3092,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774315800000},"marketStatusCode":5,"adr":0,"adjPreClose":97.51,"symbolType":"stock_kcb","openAndCloseTimeList":[[1774229400000,1774236600000],[1774242000000,1774249200000]],"highLimit":107.26,"lowLimit":87.76,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":137748133,"isCdr":false,"pbRate":10.33,"roa":"--","peRate":71.341277,"roe":"7.39%","epsLYR":1.07,"committee":-0.174603,"marketValue":12866000000,"turnoverRate":0.0027,"status":1,"afterMarket":{"amount":0,"volume":0,"close":93.4,"buyVolume":0,"sellVolume":0,"time":1774251237558,"indexStatus":"已收盘 03-23 15:30:00","preClose":97.51},"floatMarketCap":12866000000},"requestUrl":"/m/hq/s/688198","defaultTab":"news","newsList":[{"id":"2621776351","title":"3月23日佰仁医疗创60日新低，融通健康产业灵活配置混合A/B基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2621776351","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621776351?lang=zh_cn&edition=full","pubTime":"2026-03-23 16:36","pubTimestamp":1774254970,"startTime":"0","endTime":"0","summary":"证券之星消息，3月23日佰仁医疗创60日新低，收盘报93.4元，当日跌4.21%，换手率0.27%，成交量3705.0手，成交额3511.28万元。重仓佰仁医疗的前十大公募基金请见下表：根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共10家，其中持有数量最多的公募基金为融通基金的融通健康产业灵活配置混合A/B。融通健康产业灵活配置混合A/B目前规模为14.79亿元，最新净值2.621，较上一交易日下跌1.95%，近一年上涨5.73%。该公募基金现任基金经理为万民远。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032300025256.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","688198"],"gpt_icon":0},{"id":"2616803953","title":"佰仁医疗（688198）披露2025年度业绩快报公告，3月2日股价上涨4.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616803953","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616803953?lang=zh_cn&edition=full","pubTime":"2026-03-02 17:41","pubTimestamp":1772444475,"startTime":"0","endTime":"0","summary":"截至2026年3月2日收盘，佰仁医疗报收于108.1元，较前一交易日上涨4.95%，最新总市值为148.91亿元。该股当日开盘103.55元，最高109.0元，最低101.69元，成交额达8025.1万元，换手率为0.55%。近日，北京佰仁医疗科技股份有限公司发布2025年度业绩快报，营业总收入63,037.20万元，同比增长25.60%；营业利润22,336.88万元，同比增长45.78%；归属于母公司所有者的净利润20,019.03万元，同比增长36.81%。结构性心脏病板块收入同比增长26.07%，软组织修复板块增长24.23%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200026480.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","688198"],"gpt_icon":0},{"id":"2616845541","title":"每周股票复盘：佰仁医疗（688198）2025年净利增36.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616845541","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616845541?lang=zh_cn&edition=full","pubTime":"2026-03-01 02:42","pubTimestamp":1772304132,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，佰仁医疗报收于103.0元，较上周的101.51元上涨1.47%。本周，佰仁医疗2月27日盘中最高价报104.83元。本周关注点来自业绩披露要点：佰仁医疗2025年归属净利润同比增长36.81%。公司公告汇总北京佰仁医疗科技股份有限公司发布2025年度业绩快报，营业总收入63,037.20万元，同比增长25.60%；营业利润22,336.88万元，同比增长45.78%；归属于母公司所有者的净利润20,019.03万元，同比增长36.81%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100000968.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","688198"],"gpt_icon":0},{"id":"2614421834","title":"佰仁医疗发布2025年度业绩快报，盈利2.002亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614421834","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614421834?lang=zh_cn&edition=full","pubTime":"2026-02-27 18:41","pubTimestamp":1772188874,"startTime":"0","endTime":"0","summary":"证券之星消息，佰仁医疗近日即将发布2025年年报，根据2月27日发布的业绩快报，归属净利润盈利2.002亿元，同比增长36.81%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700033959.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688198","BK0251"],"gpt_icon":0},{"id":"2604292588","title":"每周股票复盘：佰仁医疗（688198）现679.72万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2604292588","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604292588?lang=zh_cn&edition=full","pubTime":"2026-01-18 03:32","pubTimestamp":1768678330,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，佰仁医疗（688198）报收于113.0元，较上周的112.01元上涨0.88%。本周，佰仁医疗1月14日盘中最高价报116.8元。1月12日盘中最低价报111.0元。佰仁医疗当前最新总市值155.66亿元，在医疗器械板块市值排名20/127，在两市A股市值排名1348/5183。本周关注点交易信息汇总：佰仁医疗1月12日发生679.72万元大宗交易交易信息汇总1月12日佰仁医疗现679.72万元大宗交易以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011800000988.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","688198"],"gpt_icon":0},{"id":"2602951361","title":"1月12日佰仁医疗现679.72万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2602951361","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602951361?lang=zh_cn&edition=full","pubTime":"2026-01-12 17:50","pubTimestamp":1768211437,"startTime":"0","endTime":"0","summary":"证券之星消息，1月12日佰仁医疗发生大宗交易，交易数据如下：大宗交易成交价格111.98元，成交6.07万股，成交金额679.72万元，买方营业部为国泰海通证券股份有限公司北京国贸证券营业部，卖方营业部为国信证券股份有限公司客户资产管理部。近三个月该股共发生3笔大宗交易，合计成交1315.0手。截至2026年1月12日收盘，佰仁医疗报收于111.98元，下跌0.03%，换手率0.3%，成交量4144.0手，成交额4632.02万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200025265.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","688198"],"gpt_icon":0},{"id":"2602536738","title":"每周股票复盘：佰仁医疗（688198）1月6日发生大宗交易成交579.91万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2602536738","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602536738?lang=zh_cn&edition=full","pubTime":"2026-01-11 04:18","pubTimestamp":1768076290,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，佰仁医疗（688198）报收于112.01元，较上周的107.01元上涨4.67%。本周，佰仁医疗1月9日盘中最高价报113.0元。1月5日盘中最低价报106.01元。佰仁医疗当前最新总市值154.29亿元，在医疗器械板块市值排名20/127，在两市A股市值排名1352/5182。本周关注点交易信息汇总：1月6日佰仁医疗发生1笔大宗交易，成交金额579.91万元交易信息汇总1月6日佰仁医疗发生1笔大宗交易，成交金额579.91万元以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100001440.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","688198"],"gpt_icon":0},{"id":"2601810739","title":"股市必读：1月6日佰仁医疗发生1笔大宗交易 成交金额579.91万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2601810739","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601810739?lang=zh_cn&edition=full","pubTime":"2026-01-07 04:10","pubTimestamp":1767730222,"startTime":"0","endTime":"0","summary":"截至2026年1月6日收盘，佰仁医疗报收于110.04元，下跌0.29%，换手率0.29%，成交量3941.0手，成交额4334.77万元。交易信息汇总资金流向1月6日主力资金净流出142.89万元，占总成交额3.3%；游资资金净流出8.28万元，占总成交额0.19%；散户资金净流入151.17万元，占总成交额3.49%。大宗交易1月6日佰仁医疗发生1笔大宗交易，成交金额579.91万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010700001850.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688198","BK0251"],"gpt_icon":0},{"id":"2600035455","title":"每周股票复盘：佰仁医疗（688198）12月29日发生大宗交易成交200.37万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2600035455","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600035455?lang=zh_cn&edition=full","pubTime":"2026-01-02 02:00","pubTimestamp":1767290440,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，佰仁医疗报收于111.02元，较上周的112.64元下跌1.44%。本周，佰仁医疗12月22日盘中最高价报112.84元。12月24日盘中最低价报107.0元。佰仁医疗当前最新总市值147.4亿元，在医疗器械板块市值排名19/127，在两市A股市值排名1324/5181。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010200000446.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688198","BK0251"],"gpt_icon":0},{"id":"2595786917","title":"12月29日佰仁医疗发生1笔大宗交易 成交金额200.37万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2595786917","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595786917?lang=zh_cn&edition=full","pubTime":"2025-12-29 17:43","pubTimestamp":1767001411,"startTime":"0","endTime":"0","summary":"证券之星消息，12月29日佰仁医疗发生大宗交易，交易数据如下：大宗交易成交价格110.7元，成交1.81万股，成交金额200.37万元，买方营业部为华鑫证券有限责任公司上海景东路证券营业部，卖方营业部为招商证券股份有限公司上海世纪大道证券营业部。近三个月该股共发生1笔大宗交易，合计成交181.0手。截至2025年12月29日收盘，佰仁医疗报收于110.7元，下跌0.29%，换手率0.2%，成交量2816.0手，成交额3112.17万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122900024138.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688198","BK0251"],"gpt_icon":0},{"id":"2590654506","title":"佰仁医疗（688198）新增【医美】概念","url":"https://stock-news.laohu8.com/highlight/detail?id=2590654506","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590654506?lang=zh_cn&edition=full","pubTime":"2025-12-12 20:30","pubTimestamp":1765542623,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，12月12日佰仁医疗新增概念。佰仁医疗主营业务：公司是国内技术领先的、专注于动物源性植介入医疗器械研发与生产的高新技术企业,产品应用于心脏瓣膜置换与修复、先天性心脏病植介入治疗以及外科软组织修复。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121200037119.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688198","BK0251"],"gpt_icon":0},{"id":"2590389595","title":"佰仁医疗(688198.SH)：胶原蛋白植入剂产品获批注册 是国内首款用于面颊部真皮层注射以改善面颊部平滑度的胶原蛋白产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2590389595","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590389595?lang=zh_cn&edition=full","pubTime":"2025-12-11 16:22","pubTimestamp":1765441360,"startTime":"0","endTime":"0","summary":"智通财经APP讯，佰仁医疗 发布公告，近日，经国家药品监督管理局审评，公司控股子公司北京艾佰瑞生物技术有限公司胶原蛋白植入剂产品注册申请获得批准，这是国内首款用于面颊部真皮层注射以改善面颊部平滑度的胶原蛋白产品。鉴于该产品为全长胶原蛋白分子，确保了其三螺旋结构的完整性;同时，高纯度满足了产品自发组装成胶原纤维，致使这款产品在结构和品质上不同于以往同类注射用胶原蛋白。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380356.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"佰仁医疗(688198.SH)：胶原蛋白植入剂产品获批注册 是国内首款用于面颊部真皮层注射以改善面颊部平滑度的胶原蛋白产品","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688198","BK0251"],"gpt_icon":0},{"id":"2588012321","title":"佰仁医疗(688198.SH)：ePTFE心包膜产品获批注册","url":"https://stock-news.laohu8.com/highlight/detail?id=2588012321","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588012321?lang=zh_cn&edition=full","pubTime":"2025-12-03 17:46","pubTimestamp":1764755172,"startTime":"0","endTime":"0","summary":"智通财经APP讯，佰仁医疗 发布公告，近日，经国家药品监督管理局审查，公司研发的心包膜产品获批注册。目前国内市场所用的心包膜为外企垄断，长期以来依赖进口，该产品的注册和上市将结束心外ePTFE心包膜依赖进口的历史。基于庞大的治疗需求，国内心脏大血管外科手术量多年来保持持续增长，2024年全国心外科总手术量约36万例，公司ePTFE心包膜产品具有广阔的应用前景，也将使更多患者受益。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377104.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"佰仁医疗(688198.SH)：ePTFE心包膜产品获批注册","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0251","688198"],"gpt_icon":0},{"id":"2580474384","title":"每周股票复盘：佰仁医疗（688198）股东户数增15.65%，Q3净利降9.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580474384","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580474384?lang=zh_cn&edition=full","pubTime":"2025-11-02 05:39","pubTimestamp":1762033154,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，佰仁医疗报收于114.55元，较上周的106.55元上涨7.51%。本周，佰仁医疗10月29日盘中最高价报116.0元。佰仁医疗当前最新总市值157.79亿元，在医疗器械板块市值排名17/126，在两市A股市值排名1202/5163。本周关注点股本股东变化：截至2025年9月30日股东户数为3962户，较6月30日增加536户，增幅15.65%。业绩披露要点：2025年第三季度归母净利润2129.63万元，同比下降9.39%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200001116.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","688198"],"gpt_icon":0},{"id":"2580541781","title":"佰仁医疗（688198）2025年三季报简析：营收净利润同比双双增长，公司应收账款体量较大","url":"https://stock-news.laohu8.com/highlight/detail?id=2580541781","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580541781?lang=zh_cn&edition=full","pubTime":"2025-11-01 06:48","pubTimestamp":1761950931,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期佰仁医疗发布2025年三季报。截至本报告期末，公司营业总收入3.82亿元，同比上升30.58%，归母净利润9269.69万元，同比上升57.93%。本报告期佰仁医疗公司应收账款体量较大，当期应收账款占最新年报归母净利润比达94.63%。去年的净利率为26.33%，算上全部成本后，公司产品或服务的附加值高。持有佰仁医疗最多的基金为圆信永丰聚优股票A，目前规模为5.58亿元，最新净值1.2968，较上一交易日下跌1.17%，近一年上涨38.56%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110100007843.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688198"],"gpt_icon":0},{"id":"2579145915","title":"图解佰仁医疗三季报：第三季度单季净利润同比下降9.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579145915","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579145915?lang=zh_cn&edition=full","pubTime":"2025-10-30 19:46","pubTimestamp":1761824805,"startTime":"0","endTime":"0","summary":"证券之星消息，佰仁医疗2025年三季报显示，前三季度公司主营收入3.82亿元，同比上升30.58%；归母净利润9269.69万元，同比上升57.93%；扣非净利润8011.52万元，同比上升44.84%；其中2025年第三季度，公司单季度主营收入1.34亿元，同比上升31.54%；单季度归母净利润2129.63万元，同比下降9.39%；单季度扣非净利润1871.69万元，同比下降17.72%；负债率17.09%，投资收益669.71万元，财务费用-59.01万元，毛利率88.17%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000040317.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688198"],"gpt_icon":0},{"id":"2579118329","title":"佰仁医疗(688198)9月30日股东户数0.4万户，较上期增加15.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579118329","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579118329?lang=zh_cn&edition=full","pubTime":"2025-10-30 17:28","pubTimestamp":1761816501,"startTime":"0","endTime":"0","summary":"证券之星消息，近日佰仁医疗披露，截至2025年9月30日公司股东户数为3962.0户，较6月30日增加536.0户，增幅为15.65%。在医疗器械行业个股中，佰仁医疗股东户数低于行业平均水平，截至9月30日，医疗器械行业平均股东户数为2.21万户。从股价来看，2025年6月30日至2025年9月30日，佰仁医疗区间涨幅为3.03%，在此期间股东户数增加536.0户，增幅为15.65%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000033126.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688198","BK0251"],"gpt_icon":0},{"id":"2570016051","title":"佰仁医疗：选举第三届董事会职工代表董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2570016051","media":"证券日报 ","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570016051?lang=zh_cn&edition=full","pubTime":"2025-09-25 22:06","pubTimestamp":1758809160,"startTime":"0","endTime":"0","summary":"证券日报网讯 9月25日晚间，佰仁医疗发布公告称，公司于2025年9月25日在公司会议室召开2025年职工代表大会，审议通过了《关于选举公司第三届董事会职工代表董事的议案》，同意选举李丽艳女士为公司第三届董事会职工代表董事。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-09-25/doc-infrtpuk1050096.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-09-25/doc-infrtpuk1050096.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688198","BK0251"],"gpt_icon":0},{"id":"2517106185","title":"佰仁医疗(688198.SH)：介入肺动脉瓣及输送系统注册申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2517106185","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517106185?lang=zh_cn&edition=full","pubTime":"2025-03-07 17:15","pubTimestamp":1741338920,"startTime":"0","endTime":"0","summary":"智通财经APP讯，佰仁医疗(688198.SH)发布公告，近日，公司自主研发的介入肺动脉瓣及输送系统提交注册申请并获国家药品监督管理局医疗器械技术审评中心正式受理。该产品主要用于复杂先天性心脏病经外科右室流出道修复与重建术后，需要经导管人工生物肺动脉瓣置换的患者，是公司进入创新医疗器械特别审查程序的第三款介入瓣产品，也是肺动脉瓣膜患者全生命周期管理系列产品的重要组成部分，同时也是列入“十三五”国家重点研发计划的重点专项产品。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1259100.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0251","688198"],"gpt_icon":0},{"id":"2517210654","title":"【佰仁医疗：介入肺动脉瓣及输送系统注册申请获受理】佰仁医疗公告，公司自主研发的介入肺动脉瓣及输送系统提交注册申请并获国家药品监督管理局医疗器械技术审评中心正式受理。受理信息如下：申请注册产品：介入肺动脉瓣及输送系统，注册受理号：CQZ2500435。该产品主要用于复杂先天性心脏病经外科右室流出道修复与重建术后，需要经导管人工生物肺动脉瓣置换的患者。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517210654","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517210654?lang=zh_cn&edition=full","pubTime":"2025-03-07 17:14","pubTimestamp":1741338855,"startTime":"0","endTime":"0","summary":"佰仁医疗公告，公司自主研发的介入肺动脉瓣及输送系统提交注册申请并获国家药品监督管理局医疗器械技术审评中心正式受理。受理信息如下：申请注册产品：介入肺动脉瓣及输送系统，注册受理号：CQZ2500435。该产品主要用于复杂先天性心脏病经外科右室流出道修复与重建术后，需要经导管人工生物肺动脉瓣置换的患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/07171448593498.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["688198","09997","BK0251","159883","BK1574","BK1222","BK1100","BK1583","09996"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1774292632282,"stockEarnings":[{"period":"1week","weight":-0.0706},{"period":"1month","weight":-0.0799},{"period":"3month","weight":-0.1505},{"period":"6month","weight":-0.14},{"period":"1year","weight":-0.1567},{"period":"ytd","weight":-0.1272}],"compareEarnings":[{"period":"1week","weight":-0.0665},{"period":"1month","weight":-0.0658},{"period":"3month","weight":-0.0272},{"period":"6month","weight":-0.0105},{"period":"1year","weight":0.1333},{"period":"ytd","weight":-0.0392}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京佰仁医疗科技股份有限公司","boardCode":"AI0035","boardName":"专用设备制造业","stockholders":"3962人(较上一季度增加15.65%)","perCapita":"34767股","listingDate":"2019-12-09","address":"北京市昌平区科技园东区华昌路2号","registeredCapital":"13774万元","survey":"　　北京佰仁医疗科技股份有限公司的主营业务是医疗器械的研发、生产、销售及服务。公司的主要产品是动物源性植介入医疗器械。","listedPrice":23.68},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"佰仁医疗(688198)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供佰仁医疗(688198)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"佰仁医疗,688198,佰仁医疗股票,佰仁医疗股票老虎,佰仁医疗股票老虎国际,佰仁医疗行情,佰仁医疗股票行情,佰仁医疗股价,佰仁医疗股市,佰仁医疗股票价格,佰仁医疗股票交易,佰仁医疗股票购买,佰仁医疗股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"佰仁医疗(688198)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供佰仁医疗(688198)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}